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Abstract
Achieving a controlled and reproducible means to direct stem cell differentiation is the single most 
critical concern scientists have been trying to address since the discovery of stem cells. In this 
regard, the use of small molecules and RNA interference offers unique advantages by targeting 
different cellular mechanisms. Our cyclodextrin-modified dendritic polyamine construct (termed 
DexAM) combines the unique properties of two distinct chemical moieties in a single delivery 
vehicle. DexAM is a single vehicle that not only solubilizes hydrophobic small molecules in 
physiological solutions, but also forms complexes with siRNA molecules, making it an attractive 
delivery system for controlling stem cell differentiation. Herein, we report the synthesis and 
application of DexAM to simultaneously deliver hydrophobic small molecules and siRNA into 
neural stem cells to significantly enhance their neuronal differentiation.
Stem cells are becoming increasingly attractive as treatment options for regenerative 
medicine due to their ability to differentiate into specialized cells and tissues of interest. 
However, achieving a controlled and reproducible means to direct stem cell differentiation is 
the single most critical concern scientists have been trying to address ever since the 
discovery of stem cells. In this regard, a chemical approach has been widely applied wherein 
small molecules are used to modulate specific signaling cascades and eventually gene 
expression within the cell. For instance, novel small molecules which can control a variety 
of stem cell fates and functions including stem cell pluripotency, differentiation and 
reprogramming have been screened and identified.1-3 Examples of such small molecules that 
have been used to modulate stem cell phenotypes include retinoic acid, cytidine analogues, 
histone-deacetylase inhibitors and protein kinase inhibitors.2 The use of small molecules to 
regulate stem cell behavior is particularly advantageous as they provide a high degree of 
temporal control over protein function by either rapid inhibition or activation of single or 
multiple targets within a protein family.3 In addition to the chemical approach, a more 
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delicate control of gene expression has been demonstrated using RNA interference (RNAi). 
RNAi has been widely used for treating genetic diseases and cancers.4,5 Many studies in the 
last decade have even demonstrated this strategy to be equally important for directing stem 
cell differentiation.6
However, a majority of small molecules tend to be very hydrophobic and lack solubility in 
physiological solutions, which can greatly impair its delivery and efficacy.7 As a result, 
organic solvents such as dimethyl sulfoxide (DMSO) are often used to dissolve such 
compounds. These solvents have shown to be cytotoxic and require careful dilution to avoid 
stem cell death and undesired side-effects.8 Similarly, a major challenge for delivering 
siRNA into stem cells is designing a robust and reliable delivery system,9 such that it allows 
high cellular viability over an extended time period after transfections to ensure the 
differentiated cellular sub-types can be effectively used for further studies (e.g. in vivo 
transplantation, animal studies, etc).10 Therefore, we believe that designing a delivery 
system which could solubilize hydrophobic small molecules in physiological solutions and 
at the same time form complexes with siRNA molecules would be significantly 
advantageous. This delivery system would enable the simultaneous delivery of siRNA and 
hydrophobic small molecules into stem cells to enhance stem cell differentiation with 
minimal cytotoxicity.
Towards this goal, herein, we demonstrate the synthesis and application of a multifunctional 
vehicle for the simultaneous delivery of siRNA molecules and hydrophobic small molecules 
to direct the differentiation of a multipotent adult stem cell line (Figure 1).
Our delivery system is a single delivery platform which provides: i) the ability to 
simultaneously deliver nucleic acids and hydrophobic small molecules to achieve a 
synergistic enhancement in stem cell differentiation, ii) high transfection efficiency of 
siRNA, and iii) minimal cytotoxicity, allowing stem cells to differentiate over longer 
periods. While such dual delivery platforms are widely prevalent for inducing apoptosis of 
cancer cells,11,12 as far as we know, this is the first demonstration showing the application 
for inducing stem cell differentiation. Unlike other dual delivery systems, we believe our 
platform is significantly novel because it not only allows for the simultaneous delivery of 
factors to direct stem cell differentiation, but also ensures long-term cell growth and 
survival.
Our cyclodextrin-modified dendritic polyamine construct (termed DexAM) combines the 
unique properties of two distinct chemical moieties in a single delivery vehicle. First, the β-
CD component serves to improve the solubility of hydrophobic compounds.13 Cyclodextrins 
are cyclical sugar molecules containing a hydrophilic exterior and hydrophobic interior, 
wherein the inclusion of hydrophobic moieties within the inner cavity serves to enhance the 
solubility, stability and bioavailability of hydrophobic small molecules.14 Given that most 
small molecules and drugs have poor water solubility and necessitate the use of cytotoxic 
organic solvents, such as DMSO, the presence of β-CD in our delivery vehicle enhances 
water solubility of drugs/small molecules and allows for optimal cellular uptake and drug 
efficacy while avoiding the use of cytotoxic solvents. Second, the dendritic polyamine 
backbone provides a high density of positive surface charge, which can be used to condense 
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negatively charged nucleic acids into cationic complexes. This would allow for effective 
intracellular delivery and endosomal escape within the stem cell.15 While maintaining a high 
degree of positive charge is crucial for proper complexation with siRNA molecules, the 
primary amines have been reported to interact with cellular components and impart 
undesired side-effects and cytotoxicity.16 Therefore, it is critical to achieve a balance 
between the cytotoxicity and complexation capacity of our DexAM construct.
The DexAM molecule was synthesized by using a multistep solution-phase and solid-phase 
synthesis (see Supporting Information for detailed experimental methods) developed by our 
group in a previous study.17 Briefly, the dendritic polyamine backbone was synthesized by 
the Michael addition of tris(2-aminoethyl)amine and methyl acrylate, followed by amidation 
of the amino esters generated after Michael addition (Figure 2). Thereafter, this synthetic 
route (Michael addition followed by amidation) was repeated to yield a polyamine backbone 
consisting of 48 primary amines. The conjugation of β-CD to the polyamine backbone was 
performed by the tosylation of β-CD, followed by nucleo-philic addition to the amine group. 
By integrating the peaks of the β-CD protons (49 methylene protons) and the polyamine 
protons (161 methylene protons), we found that the β-CD was covalently bound to the 
polyamine in a molar ratio of 3:1. This molar ratio was found to be optimal, providing a 
good balance between the high loading capacity of the hydrophobic small molecule and the 
zeta potential required for siRNA complexation and delivery, as described below. This 
yielded our final DexAM molecule, which was used for the dual delivery of siRNA and 
small molecules to NSCs.
We optimized the siRNA delivery using DexAM by suppressing the expression of green 
fluorescent protein (GFP) in NSCs that were genetically modified to express GFP (Figure 
3a). However, prior to knocking down GFP expression within the NSCs by delivering 
siRNA using DexAM, we evaluated the capability of DexAM to spontaneously form 
complexes with the negatively charged siRNA. Using a well-established dye exclusion assay 
(Picogreen Assay), we identified a range of DexAM concentrations which showed about 
75% of the siRNA binding to the DexAM molecule (Figure S1).
Thereafter, varying concentrations of the DexAM molecule was mixed with a given amount 
of GFP siRNA (100 pmol) to form the DexAM-siRNA complexes. The zeta potential of the 
resulting complexes were found to be in the range of 10-12 mV at pH 7.4, while exhibiting 
hydrodynamic diameters of 300 to 350 nm. In order to visualize the efficiency of delivery, 
the DexAM molecule was conjugated with a fluorescent dye (AlexaFluor® 594) prior to 
complexation with the GFP siRNA. The decrease in green fluorescence intensity was 
monitored using florescence microscopy over a time period of 48-96 h (Figure 3b,c). 
Successful transfection of the DexAM-siRNA constructs was evident as visualized by the 
presence of the dye fluorescence expression (conjugated to DexAM) in the NSCs (Figure 
3c). The siRNA transfection efficiency and distribution within the cellular cytoplasm was 
further confirmed by delivering dye-labeled siRNA (Silencer® negative control Cy3-labeled 
siRNA, Ambion) complexed with unlabeled-DexAM (Figure S2). We observed a dose-
dependent knockdown of GFP expression, wherein the NSCs treated with 75 μM DexAM 
(complexed with GFP siRNA) showed a significant 80% knockdown in GFP intensity after 
96 hours of siRNA treatment compared to the untreated control cells (Figure 3b). In 
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contrast, maximal GFP knockdown of only 33% was observed with commercial transfection 
reagents at the recommended doses (Figure S3). The high efficiency of siRNA delivery and 
knockdown by DexAM can be attributed to the presence of the highly dense primary amine 
groups on the surface in addition to the highly symmetrical and three-dimensional spherical 
structure of DexAM.18
While we achieved a remarkable knockdown efficiency with the DexAM-siRNA constructs, 
maintaining high cellular viability was equally important. Evaluating the cytotoxicity of the 
DexAM molecules is especially critical for applications in stem cell biology, which 
generally require both longer time periods of culture (at least one week) and differentiated 
sub-type specific cells that are functionally active for subsequent in vitro and in vivo studies. 
We assessed the cytotoxicity of the DexAM molecules using the MTS assay, which 
confirmed that our delivery vehicle shows negligible toxicity (Figure S4). In addition, NSCs 
treated with DexAM for siRNA delivery showed much higher cellular viability compared to 
those treated with commercially available transfection reagents at the recommended doses 
(Figure S5). While cationic polyamine-based polymers have been observed to show dose-
dependent cytotoxicity in mammalian cells, we believe the biocompatibility of our DexAM 
constructs is due to the presence of CD, which can reduce the nonspecific binding of the 
DexAM with cellular proteins and components.16,19
Having demonstrated the efficient gene silencing capability of DexAM by delivering siRNA 
against GFP, we focused on using our delivery vehicle for codelivering siRNA and small 
molecules to enhance the neuronal differentiation of NSCs. For the siRNA molecule, we 
designed a sequence to knockdown a well-established transcription factor known as SOX9, 
which acts as a switch between neuronal and glial differentiation.20 When the SOX9 gene is 
“turned on,” a higher percentage of NSCs differentiate into astrocytes (glial cells), and when 
“turned off,” a higher percentage of NSCs differentiate into neurons.21 For the small 
molecule, we selected the well-known vitamin A derivative all-trans retinoic acid (RA), 
which is known to play a crucial role in central nervous system development. RA functions 
by binding to RA receptors (RARs) in the cellular nucleus to form a ligand-receptor 
complex, which in turn binds to RA response elements to activate gene expression.22 
However, this activation first requires the efficient intracellular delivery of RA into the 
cytoplasm, whereby the binding of RA to cytoplasmic proteins facilitates the 
abovementioned downstream effects in the nucleus. Previous studies have reported that the 
treatment of RA tends to upregulate the expression of a variety of neuronal genes in cultured 
stem cells.21,23 Interestingly, exogenous expression of a SOX9 gene prior to the RA 
treatment was found to actually counteract the neuronal-promoting effect caused by RA, by 
suppressing neuronal gene expression.21 SOX9 is thus known to actively induce glial traits 
while simultaneously repressing neuronal traits. The knock-down of SOX9 using siRNA 
(siSOX9) and exposure to RA in NSCs has each individually been demonstrated to induce 
NSC differentiation into neurons. However, the two factors have varying mechanisms of 
action and target different signaling pathways in NSCs: RA forms a complex to modulate 
gene expression at the transcriptional level in the nucleus, while siSOX9 forms a RNA-
induced silencing complex (RISC) to modulate gene expression at the post-transcriptional 
level in the cytoplasm. Thus, we hypothesized that the simultaneous treatment with RA and 
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suppression of SOX9 could greatly enhance the neuronal differentiation of NSCs. To this 
end, we utilized our DexAM construct to facilitate the co-delivery of RA and siSOX9 
(Figure 4a).
RA has been used in previous studies for inducing neuronal differentiation, but given that it 
is extremely hydrophobic, it requires the use of toxic organic solvents like DMSO for 
delivery. For our studies, RA was loaded within the β-CD cavity of DexAM under reflux 
conditions to obtain highly water soluble complexes, thus evading the use toxic organic 
solvents (see Supporting Information for details).
By refluxing varying equivalents of RA with a given constant amount of DexAM, the RA 
encapsulation efficiency per β-CD was determined to be ~77% (Figure S6).
Thereafter, the RA-loaded DexAM (2 μM RA) was complexed with the negatively charged 
siRNA (100 pmol; as described earlier) to form the DexAM constructs containing the 
siSOX9 and RA in a single delivery vehicle (Figure 4a). The NSCs were plated into culture 
plates at Day 0, followed by transfection with the DexAM-RA-siSOX9 constructs at Day 1. 
To confirm our hypothesis that the simultaneous delivery of RA and siSOX9 would enhance 
neuronal differentiation, we also transfected NSCs with: 1) DexAM complexed with RA 
(and Silencer® negative control siRNA to maintain the charge ratio), 2) DexAM complexed 
with only siSOX9 (without RA), and 3) control (untreated) cells. At Day 6, we quantified 
the extent of differentiation by immunostaining for neuronal (TuJ1) and glial (GFAP) 
markers (Fig. 4b and 4c). The control (untreated) cells showed the majority of the NSCs 
differentiated into glial cells (~70%) versus neuronal cells (~25%), which is an expected 
differentiation pattern as observed previously.24 Conditions containing DexAM delivery of 
only RA and only siSOX9 resulted in about a two-fold increase in neuronal differentiation 
compared to the control, showing about 49% and 53% of the cells expressing the neuronal 
marker TuJ1, respectively (Figure 4b). Compared to the various control treatment conditions 
(Figure S7), the simultaneous delivery of RA and siSOX9 to the NSCs using our DexAM 
molecule resulted in a remarkable increase in neuronal differentiation, wherein in about 71% 
of the cells were expressing TuJ1 (Figure 4b). The enhanced neuronal differentiation using 
the combined DexAM-RA-siSOX9 construct was found to be statistically significant, 
confirming the synergistic effect of combining RA and siSOX9 for a single treatment to 
control NSC behavior.
In summary, the introduction of exogenous nucleic acids combined with small molecules 
into stem cells represents a powerful approach for manipulating stem cell behaviors. This is 
the first demonstration where a delivery platform capable of efficient and simultaneous 
delivery of siRNAs and hydrophobic small molecules has been shown to direct stem cell 
differentiation. Our synthetic methodology allows for facile manipulation of the core 
chemical structure to attain remarkable transfection efficiency while maintaining negligible 
cytotoxicity, thus allowing long-term cell survival. More-over, our multimodal delivery 
vehicle enables a methodology by which we can target multiple signaling pathways and 
mechanisms to successfully enhance the neuronal differentiation of neural stem cells. With 
the increasing interest in achieving precise control over stem cell differentiation, our 
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DexAM delivery system serves as a step towards bridging the gap between basic science 
and clinically-relevant treatments.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
(A) DexAM is complexed with siRNA via electrostatic interaction and the small molecule 
via β-cyclodextrin encapsulation. (B) DexAM constructs are delivered to neural stem cells 
(NSCs) to enhance differentiation into neurons.
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Figure 2. 
The polyamine backbone is initially synthesized by the iterative Michael addition of tris(2-
aminoethyl)amine and methyl acrylate, followed by amidation. Tosylated β-cyclodextrin is 
then attached to form the final DexAM molecule.
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Figure 3. 
(A) Scheme depicting the delivery of DexAM complexed with siRNA targeting GFP to 
NSCs. (B) Quantitative comparison of the percentage of GFP knockdown at 96 hrs in NSCs 
with varying concentrations of DexAM. (C) Fluorescence images of cell with varying 
concentrations of DexAM showing GFP expression (green) and dye-labeled DexAM (red) at 
96 hrs. Scale bars: 20 μm.
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Figure 4. 
(A) Complexation to DexAM. (B) Quantification of the percentage of cells expressing 
neuronal TuJ1 and glial GFAP at 6 days. Student’s unpaired t-test was used for evaluating 
the statistical significance for cells stained for TuJ1, compared to the RA-siSOX9 treatment 
(* = P < 0.001). (C) Fluorescence images of cells stained for the nucleus (blue), TuJ1 (red, 
top row) and GFAP (green, bottom row) at Day 6. Scale bars: 20 μm.
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